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Introduction
The bacterial genome encodes two types of topoisomerases, I and II which differ in the mechanism of DNA strand breakage [1] . The type II topoisomerases consist of two types, DNA gyrase and topoisomerase IV (TopoIV). These enzymes play essential roles in DNA replication by managing the topological states of DNA in the cell [2, 3] . In prokaryotes, type II topoisomerases consist of two subunits and are functional in tetrameric form, which is different from the eukaryotic type II topoisomerases that exist as homodimers [3] . Prokaryotic DNA gyrase contains two gyrase A (GyrA) and gyrase B (GyrB) subunits respectively to form the heterotetramer. For Escherichia coli (E. coli), GyrA is a 97kDa protein that is involved in DNA binding and GyrB, it is a 90kDa protein with an N-terminal ATP binding domain [4] .
Interfering with bacterial DNA replication by targeting type II topoisomerases has been shown to be an efficient strategy to develop antibacterial agents [5] . Successful examples include the fluoroquinolone class of antibiotics [6] . Many other novel and potent inhibitors have been developed in recent years [7] . The N-terminal domain of the type II topoisomerases contains the ATP binding pocket and has been of great interest in drug development because this domain exhibited high sequence homology among pathogenic bacteria and low homology with eukaryotes [5, 7] . Structure-based drug design has been demonstrated to be a powerful tool in developing inhibitors targeting both GyrB and TopolV ATP binding domains. Several classes of inhibitors have been discovered using this approach [8] [9] [10] [11] .
The structures of the N-terminal ATP binding domains of both GyrB and E subunit of TopoIV (ParE) from E. coli have been reported [12, 13] . The structures of GyrB/ParE and inhibitor complexes demonstrated that most of the inhibitors are binding with the ATP binding pocket [9] . Although the structure of this domain is similar among the type II topoisomerases, a single residue difference among different topoisomerases can result in different inhibitor potency [2] . Understanding protein-inhibitor interactions will provide useful information in the drug development process. NMR spectroscopy has been proven to be a useful tool in drug development [14] . Despite the extensive X-ray studies of GyrBs and ParEs, few NMR studies have been conducted for the N-terminal domain of GyrB and ParE from bacteria except for the assignments of the P24 fragment of Staphylococcus aureus and the N-terminal 24kDa fragment of GyrB from E. coli [15, 16] .
In this study, we obtained the N-terminal 24kDa domain of the GyrB from Pseudomonas aeruginosa (P. aeruginosa) (referred as pGyrB) for NMR studies. As the structure of this domain is not available, structural information for this domain will be useful for structure-based drug design because P. aeruginosa is an important pathogenic species. We managed to obtain the backbone assignments for both free and inhibitor-bound forms of pGyrB. The secondary structure and dynamic property of pGyrB in solution were analyzed and the bis-pyridylurea inhibitor was shown to bind to the ATP binding pocket.
Materials and methods

Sample preparation
The cDNA encoding the pGyrB was amplified by polymerase chain reaction using genomic DNA of P. aeruginosa as a template and cloned into NdeI and XhoI sites of pET29b. The resulting plasmid can express residues 1-222 of GyrB and extra 8 residues (LEHHHHHH) at the C-terminus. To express pGyrB from E. coli, the plasmid was transformed in E. coli (BL21DE3) competent cells. The recombinant protein was expressed and purified using affinity purification and gel filtration chromatography [17, 18] . Briefly, several colonies were picked up from the plate and inoculated in 20 mL of M9 medium. The overnight culture at 37°C was then transferred into 1 L of M9 medium. The recombinant protein was induced for 18 h at 18°C by adding b-D-1-thiogalactopyranoside (IPTG) to 1 mM. The E. coli cells were harvested by centrifugation and the recombinant protein was purified in a buffer that contained 20 mM sodium phosphate, pH 6.5, 80 mM KCl, 2 mM DTT and 0. 5 H-labeled proteins were used in NMR data acquisition. Two-(2D) and three-dimensional (3D) experiments and transverse relaxation-optimized spectroscopy (TROSY) [19, 20] -based experiments including HSQC, HNCACB, HNCOCACB, HNCOCA, HNCA, HNCACO and HNCO were collected and processed. For pGyrB and inhibitor complex, protein was first purified and inhibitor was then added into the solution to a protein: inhibitor molar ratio of 1:1.2. Inhibitor was synthesized and purified as described [21] . All the experiments were conducted at 25°C on a Bruker Avance 700 spectrometer equipped with a cryoprobe. All the spectra were processed using NMRPipe [22] or Topspin 2.1 and analyzed using NMRView [23] and CARA (http:// www.mol.biol.ethz.ch/groups/wuthrich_group). The secondary structure was analyzed using TALOS+ based on the backbone chemical shifts [24] . [25] . To obtain protein-inhibitor inter-molecular NOEs, a NOESY-TROSY experiment with a mixing time of 100 ms was recorded using a sample that contained 0.5 mM of 13 
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H-labeled pGyrB and 1 mM of inhibitor.
Effect of inhibitor on protein thermal stability
Thermal shift experiment was carried out on a Roche LC480 PCR machine. Each assay well contained 10 lM pGyrB, 20Â spyro N-TROSY spectra of pGyrB. The NMR spectra of pGyrB in the absence (black) and presence (red) of the inhibitor were collected and superimposed, and two peaks that undergo significant shifts upon complex formation are highlighted. Inside spectra are selected regions of spectra with inhibitor/protein ratios of 0 (black), 0.5 (green) and 1 (red), respectively. The interaction is undergoing slow exchange. (B) 3D-HNCACB of pGyrB in the absence and presence of the inhibitor. Select strips of HNCACB spectrum for several residues are shown. Upper and lower panels are free and inhibitor-bound pGyrB, respectively. The peaks are labeled with residue number and atom types.
orange. The assay buffer contained 50 mM HEPES, pH 7.2, 250 mM NaCl and 5 mM MgCl 2 .
Isothermal Titration Calorimetry (ITC) experiment
ITC experiment was performed on an Auto-iTC200 instrument (Microcal Inc.). The experiment was carried out at 25°C. Protein was prepared in a buffer that contained 50 mM HEPES, pH 7.5, 250 mM NaCl and 5 mM MgCl 2 at concentrations of 100 lM.
Inhibitor was prepared in the same buffer and loaded into the syringe automatically. Titration was carried out with 18 injections over a period of 40 min with stirring at 1000 rpm.
Protein relaxation analysis
The 15 N longitudinal T 1 , and transverse T 2 relaxation rates and
N-heteronuclear NOE (hetNOE) experiments [26] were collected at 298 K using a purified pGyrB sample in the absence and presence of the inhibitor at a Bruker Avance 700 MHz magnet. For T 1 measurements, the relaxation delays of 100, 300, 500, 1000, 1400, 1800, 2000, 2500 and 3000 ms were recorded. For T 2 measurements, the data were acquired with delays of 16.9, 34, 51, 68, 85, 102, 119, 136 and 153 ms. The hetNOE was obtained using two datasets that were collected with and without initial proton saturation for a period of 3 s. The collected spectra were then processed with NMRPipe [22] and analyzed with NMRView [23] .
Results
NMR spectra of pGyrB
Structural studies of GyrB from E. coli revealed that the N-terminal ATP binding domain contains eight b-strands backed on the side with several helices [27] . Free pGyrB exhibited well dispersed cross peaks in 1 H-15 N-TROSY spectrum (Fig. 1A) , which also suggested that it constrains b-strands. The OD 280 /OD 260 of purified protein was approximately 0.6, suggesting that pGyrB sample does not contain any nucleotides. Protein aggregation was observed when the sample was kept at room temperature for more than 2 days. Although 3D NMR experiment data were collected for backbone assignment, the data quality was not good enough to complete the assignment using the conventional strategy due to the weak signal in the HNCACB experiment (Fig. 1B) . In the presence of bis-pyridylurea, a potent inhibitor of both ParE and GyrB of E. coli [21] , chemical shift perturbation was observed, suggesting that pGyrB binds to the inhibitor in solution (Fig. 1A) . The protein-inhibitor complex was stable for more than 7 days and the quality of the 3D spectra was improved (Fig. 1B) , which made the backbone assignment possible. Both thermal shift assay (TSA) and ITC were carried out to understand protein-inhibitor interactions. TSA showed that thermal shift (DTm) caused by inhibitor binding was more than 9°C ( Fig. 2A) . ITC result suggested that the binding affinity (K D ) was 54.6 nM and reaction stoichiometry (n) was approximately 1 (Fig. 2B) , which explained the interaction was undergoing slow exchange observed in the NMR study (Fig. 1) .
Backbone assignment of free pGyrB and complex
Backbone resonance assignment for the pGyrB-inhibitor complex was obtained using conventional 3D experiments. The assignments of the 1 H-15 N-TROSY spectra of pGyrB in the absence and presence of the inhibitor are shown in Fig. 3A . Most of the backbone amides and amide protons were assigned except M1, L100 and V120. Other backbone resonance assignments including Ca 1A and 2 ).
Secondary structural analysis of pGyrB and the complex
The secondary structure analysis for pGyrB in the absence and presence of the inhibitor was conducted using TALOS+ [24] . Both forms showed similar secondary structural elements to E. coli N frequencies is shown with residue name and sequence number. (C) Secondary structure analysis of pGyrB. Box indicates helical structures. Arrow indicates strands and line indicates loops. Secondary structural elements for free pGyrB derived from NMR study and eGyrB derived from X-ray structures (PDB ids 1EI1 and 4PRX) are shown in black and red, respectively. The inhibitorbound pGyrB has the same secondary structural elements as free pGyrB. The sequence alignment was conducted using ClustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2/). The different residues between eGyrB and pGyrB are highlighted in red. (D) Homology model of pGyrB. A model was built using structure of GyrB of E. coli as a template. Left panel is the crystal structure of eGyrB (PDB id 1EI1). The ADPNP is show in sticks. Middle panel is surface representation of the eGyrB-ADP complex. The right panel is the model of pGyrB. GyrB (Fig. 3C ). There are eight b strands including b1 (residues C58-I65), b2 (residues S70-N76), b3 (residues E131-R138), b4 (residues K141-H148), b5 (residues L156-T162), b6 (residues S165-F171), b7 (residues V202-D208) and b8 (residues K213-E220) and five a helices including a1 (residues L18-M27), a2 (residues T36-A55) a3 (residues A92-T98), a4 (residues V122-L128) and a5 (residues W185-L198) present in the pGyrB. The pGyrB shares very high sequence homology (more than 75% sequence identity) with GyrB of the E. coli (eGyrB). The secondary structures of pGyrB derived from NMR data are similar to X-ray structure of eGyrB, except that there is a short helix present at the N-terminus of eGyrB, and the lengths of a1, a2, b1, a4, b3, b5, b6, and b8 are slightly different (Fig. 3C ). There are several residues that are different between these two proteins (Fig. 3C ). Although the difference did not alter the structure of pGyrB, it may affect inhibitor binding because some of different residues are at the inhibitor binding regions (Fig. 3C) . A homology model of pGyrB was built using the SWISS-MODEL server (Fig. 3D ) using the X-ray structure of eGyrB bound with adenylyl-imidodiphosphate (ADPNP) as a template [2, 28] . Long-range NOEs of residues in the b-strands of pGyrB were observed, which supports the homology model (data not shown).
The bis-pyridylurea inhibitor binds to the ATP binding pocket
To determine which residues were affected by inhibitor binding to pGyrB, CSP caused by inhibitor binding was plotted against residue number (Fig. 4A) . As the chemical shifts of amide and amide protons are sensitive to the environment, residues showing significant CSP might be involved in inhibitor binding. It was clear that those residues from the a2, b2, b6, the loop between b2 and a3, a3 and a4 were important for inhibitor interaction (Fig. 4A) .
Whether the inhibitor could cause structural changes on pGyrB was investigated by analyzing the changes of the Ca chemical shifts that are sensitive to the secondary structures. Although several residues showed changes in the Ca chemical shifts (Fig. 4B) , the overall structure of pGyrB was not altered as analyzed by TALOS+ (Fig. 3) . The residues from a2 including 44-52 are affected significantly in the presence of the inhibitor, suggesting that they are critical for inhibitor binding. This result may also explain the high quality HNCACB experiment obtained for the complex because the inhibitor can affect the chemical environments of Ca and Cb carbons. Residues showing CSPs were mapped to the homology model of pGyrB (Fig. 4C) . Compared with the X-ray structure of the ParE-inhibitor complex, the inhibitor also binds to the ATP binding pocket of pGyrB (Fig. 4D) . NOEs between residues and inhibitor were also observed and the orientation of the inhibitor in pGyrB is similar to the one in ParE of Streptococcus pneumonia (S. pn).
Backbone relaxation analysis of pGyrB and its complex
Backbone relaxation data T 1 , T 2 and hetNOE revealed the dynamic properties of both free and inhibitor bound pGyrB (Fig. 5) . Compared with complex, fewer residues of free pGyrB were used for analysis because the peaks are too weak to be accurately analyzed. Surprisingly, there is no significant change observed for these relaxation parameters in the absence and presence of the inhibitor. The N-terminal 25 residues and the C-terminal 5 residues are flexible in the absence and presence the inhibitor, which is characterized with low T 1 and hetNOE values and high T 2 values (Fig. 5) . The average T 1 values excluding both N-and C-terminal residues and the loop between a3 and a4 for free pGyrB and complex are 1.43 s and 1.48 s, respectively. The average T 2 values are 37.7 and 37.2 ms, respectively. The loop a3 and a4 compassing residues 100-120 is flexible for both free pGyrB and complex, suggesting that the loop is not involved in the molecular interaction with this inhibitor. The hetNOE values of other residues are higher than 0.82 that is expected for NH groups in a grid globular protein [26] , indicating that these residues are rigid in solution. Further dynamic study in other time scales or protein side chain relaxation study will be helpful for understanding the effect of inhibitor on GyrB dynamics.
Discussion
Due to the bacterial resistance to antibiotics, there is a great need to develop novel antibacterial agents. The rate-limiting steps in the antibacterial discovery process are twofold [29] . First, it is important to select a target that is not prone to resistance development and second, it is important to increase chemistry diversity to overcome the barriers to bacterial entry [29] . Bacterial type II topoisomerases have been proven to be a good target for antibacterial development due to their high sequence homology among the pathogenic bacteria and low homology with eukaryotes [5, 7] . Structure-based drug design has been an important tool in the development of these novel inhibitors such as tricyclic GyrB/ParE inhibitors and azaindole class of antibacterial agents [7, 10, 30] . Understanding protein and inhibitor interaction is important in drug development. In this study, we carried out NMR studies on the pGyrB. It is interesting that the assignment for the free pGyrB was challenging due to the protein stability and low signal sensitivity (Fig. 1B) , which might be the reason that there is no structural information available for both ParE and GyrB from P. aeruginosa, an extremely important Gram-negative strain with high pathogenicity. In the presence of the inhibitor that binds to pGyrB with a K D of 54.6 nM, the protein stability was improved ( Fig. 2A) and we obtained backbone resonance assignments for both free and inhibitor bound forms of pGyrB (Fig. 3) . The secondary structural elements of pGyrB in solution were determined based on the assignment (Fig. 3) . Although the inhibitor binds to pGyrB with an affinity in nanomolar range, there was no significant secondary structural change observed for pGyrB upon inhibitor binding. Further relaxation results also demonstrated that the backbone dynamic of pGyrB was not changed dramatically (Fig. 5) . It has been noted that our 3D spectra and relaxation data suggest that the side chain dynamics of residues in the ATP binding pocket might be important for ligand binding. In the presence of the inhibitor, the backbone amide dynamics of pGyrB were not affected significantly, while the side chain dynamics was influenced (Figs. 1B and 2A) . These results imply that careful protein 
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N relaxation parameters for pGyrB in free (s) and inhibitor bound forms (N). Unanalyzed residues include prolines and the ones that are overlapped or too weak to be quantified. The relaxation experiments were collected using a sample that contained 0.6 mM and ligand interaction need to be studied in drug development because the binding affinities between the inhibitor and eGyrB/ ParE might be different from pGyrB due to the difference of residues in the ATP binding pocket. Our study on the ParE of S. pn showed that swapping a single residue with a corresponding residue in P. aeruginosa in the ATP binding pocket can affected inhibitor binding affinity (Kang et al., unpublished data). Our study also confirmed that the loop between a3 and a4 of pGyrB was not involved in inhibitor binding because there were no CSP observed and dynamic changes were minor in the presence of the inhibitor (Fig. 5) .
The inhibitor used in this study is a pyridylurea scaffold derived from fragment-based drug design and is ATP competitive [21] . Its activity against gram-negative strains such as E. coli and grampositive strains was investigated in detail [21] . X-ray crystal structure revealed that D78 of b2 and T172 of b6 from ParE of S. pn formed hydrogen bonds with the inhibitor. R81 and M83 from S. pn ParE from the loop between b2 and a3 were shown to interact with the inhibitor [21] . We carried out biophysical characterization for the molecular interaction between pGyrB and the inhibitor ( Figs. 1 and 2 ). Based on the backbone resonance assignment, the CSP caused by inhibitor binding was investigated in this study. Residues from b2 (D75), b6 (E168 and V169), loop between b2 and a3, and a3 were shown to be important for inhibitor binding (Fig. 4) . Residues exhibited CSP with more than 0.2 ppm upon inhibitor binding were localized at the ATP binding pocket (Fig. 4) . NOEs between pGyrB and the inhibitor were observed (Fig. 4) , which further confirmed the residues that are important for inhibitor binding. Our results provide direct evidence to show that the bis-pyridylurea inhibitor binds to the ATP binding pocket of pGyrB, which is similar to the ParE of S. pn. These results will be useful to understand protein and inhibitor interactions, which will be helpful in antibacterial drug development. Although it will be useful to carry out further studies to understand protein dynamic in other time scales, this study provides an example to show that inhibitors or ligands can facilitate structural studies of proteins by improving spectral quality.
In summary, we purified pGyrB and conducted structural studies and its interaction with a bis-pyridylurea inhibitor. This inhibitor binds to pGyrB with a K D of 54.6 nM and could improve its thermal stability. Secondary structures of pGyrB were defined and inhibitor did not cause significant conformational changes. CSP and NOE analysis demonstrate that the inhibitor binds to the ATP binding pocket.
